Neuropace
NPCE
41 hedge funds and large institutions have $182M invested in Neuropace in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 11 reducing their positions, and 4 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
36% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 11
28.04% more ownership
Funds ownership: 46.05% → 74.09% (+28%)
5% more funds holding
Funds holding: 39 → 41 (+2)
2% more capital invested
Capital invested by funds: $177M → $182M (+$4.15M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$8.3M |
| 2 |
Morgan Stanley
New York
|
+$3.36M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$2.13M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.77M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$248K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$7.05M |
| 2 |
Amundi
Paris,
France
|
-$1.29M |
| 3 |
Millennium Management
New York
|
-$1.13M |
| 4 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
-$879K |
| 5 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$238K |
NPCE Hedge Fund Activity: Q4 2021 in Review
41 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q4 2021, worth a combined $182M — up 2.3% from $177M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NPCE positions and 4 closed out — a net gain of 2 holders — while 15 added to existing stakes and 11 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $8.3M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $7.05M sold.
- 41 institutional investors held Neuropace (NPCE) as of Q4 2021, up from 39 in Q3 2021.
- Funds reported $182M of Neuropace stock for Q4 2021, up 2.3% quarter-over-quarter.
- 6 funds opened new Neuropace positions in Q4 2021 and 4 closed out, a net change of +2 holders.
- The largest Neuropace buyer in Q4 2021 was Soleus Capital Management, an estimated $8.3M added.
- The largest Neuropace seller in Q4 2021 was Sectoral Asset Management, an estimated $7.05M sold.
Based on aggregated 13F filings for Q4 2021.